Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny—and what nuances do you need to know? Let’s dig in.
By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' executives voiced confidence in its ...
Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides ...
Details suggest two separate medications may present health risks.
High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...
When eating, the body converts extra calories, especially from carbs, sugar, fats, and alcohol, into triglycerides. Triglycerides are a form of fat or lipid, which the body stores away into its fat ...
Low cholesterol can reduce the risk of dementia, a new University of Bristol-led study with more than a million participants has shown. The research, led by Dr. Liv Tybjærg Nordestgaard while at the ...
A drug originally developed to treat type 2 diabetes may protect the heart. Early research shows IC7Fc can lower cholesterol, ...
Heart-disease–linked LDL cholesterol fell by some 10 percent after 48 hours on the diet in test subjects with metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results